Despite a median treatment time of 9.5 hours after stroke onset - more than twice the current therapeutic window - JX10 showed significantly better functional outcomes than placebo with no symptomatic intracranial hemorrhage events.
Women with systolic BP ≥140 mm Hg at age 40 face a striking 4x higher stroke risk over 30 years compared to those with optimal BP, new cohort study reveals.